Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine
- 1 August 2006
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 25 (1), 34-42
- https://doi.org/10.1016/j.vaccine.2006.07.022
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox VirusJournal of Virology, 2005
- Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID miceVaccine, 2005
- Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypoxNature, 2004
- Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen DeliveryCurrent Drug Targets - Infectious Disorders, 2003
- Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaquesVaccine, 2001
- Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.Journal of General Virology, 1998
- Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.Journal of General Virology, 1998
- Nonreplicating vaccinia vector efficiently expresses recombinant genes.Proceedings of the National Academy of Sciences of the United States of America, 1992
- Human Monkeypox: A Newly Emerged Orthopoxvirus Zoonosis in the Tropical Rain Forests of AfricaThe American Journal of Tropical Medicine and Hygiene, 1985
- MVA-Stufenimpfung gegen PockenDeutsche Medizinische Wochenschrift (1946), 1974